Our findings thus suggest that the pharmacological activation of the adiponectin-AMPK-FOXO-signaling pathway may be therapeutically beneficial in counteracting NAFLD/NASH, consistent with other proposals24, 25. The gene discussed is PRKAA1; the disease is metabolic dysfunction-associated steatotic liver disease.